Phase II trial of MVI 816 in men with PSA-recurrent non-metastatic prostate cancer.

Trial Profile

Phase II trial of MVI 816 in men with PSA-recurrent non-metastatic prostate cancer.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2014

At a glance

  • Drugs MVI 816 (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Jan 2014 New trial record
    • 13 Jan 2014 Madison Vaccines has closed an $US8 million Series A financing, the proceeds of which will partly go towards completion of this trial, according to a Madison Vaccines media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top